Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$572M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$495M |
| 3 |
iShares MBS ETF
MBB
|
+$405M |
| 4 |
Procter & Gamble
PG
|
+$365M |
| 5 |
Microsoft
MSFT
|
+$327M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$605M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$544M |
| 3 |
Sempra
SRE
|
+$474M |
| 4 |
CELG
Celgene Corp
CELG
|
+$411M |
| 5 |
BPL
Buckeye Partners, L.P.
BPL
|
+$380M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.85% |
| 2 | Healthcare | 5.77% |
| 3 | Financials | 5.26% |
| 4 | Consumer Discretionary | 4.71% |
| 5 | Communication Services | 4.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2726
HUB Group
HUBG
$2.92B
| $2.55M | ﹤0.01% |
99,512
-2,138
| -2% | -$52.9K |
|
2727
Enpro
NPO
$7.05B
| $2.55M | ﹤0.01% |
38,105
+5,084
| +15% | +$338K |
|
2728
PUT
Yum China
YUMC
$16.3B
| $2.54M | ﹤0.01% |
53,000
-2,800
| -5% | -$124K |
|
2729
CALL
VeriSign
VRSN
$26.6B
| $2.54M | ﹤0.01% |
13,200
+10,300
| +355% | +$1.94M |
|
2730
Corcept Therapeutics
CORT
$12B
| $2.54M | ﹤0.01% |
209,871
+102,558
| +96% | +$1.43M |
|
|
GAZ
2731
DELISTED
iPath Series B Bloomberg Natural Gas Total Return Sub-Index ETN
GAZ
| $2.53M | ﹤0.01% |
100,000
| – | – |
|
2732
Northwest Bancshares
NWBI
$2.28B
| $2.53M | ﹤0.01% |
152,218
+27,192
| +22% | +$454K |
|
2733
CALL
Copart
CPRT
$27.5B
| $2.53M | ﹤0.01% |
111,200
+82,000
| +281% | +$1.75M |
|
2734
PUT
Murphy Oil
MUR
$4.78B
| $2.52M | ﹤0.01% |
94,200
-237,400
| -72% | -$5.45M |
|
2735
CALL
Regions Financial
RF
$26.8B
| $2.52M | ﹤0.01% |
147,000
+51,600
| +54% | +$850K |
|
2736
iShares ESG Optimized MSCI USA ETF
SUSA
$4.18B
| $2.52M | ﹤0.01% |
37,630
| – | – |
|
|
PFPT
2737
DELISTED
Proofpoint, Inc.
PFPT
| $2.52M | ﹤0.01% |
21,969
+10,058
| +84% | +$1.2M |
|
2738
CALL
ProShares UltraPro S&P 500
UPRO
$5.7B
| $2.52M | ﹤0.01% |
72,000
+21,400
| +42% | +$655K |
|
|
INFN
2739
DELISTED
Infinera Corporation Common Stock
INFN
| $2.51M | ﹤0.01% |
316,207
+111,721
| +55% | +$687K |
|
2740
Appian
APPN
$2.48B
| $2.5M | ﹤0.01% |
65,554
-518,703
| -89% | -$22.4M |
|
|
MNDT
2741
PUT
DELISTED
Mandiant, Inc. Common Stock
MNDT
| $2.5M | ﹤0.01% |
151,500
+11,800
| +8% | +$189K |
|
2742
Bruker
BRKR
$8.14B
| $2.5M | ﹤0.01% |
49,077
-59,366
| -55% | -$2.83M |
|
2743
Sanofi
SNY
$104B
| $2.5M | ﹤0.01% |
49,759
+37,984
| +323% | +$1.78M |
|
2744
CALL
Dillards
DDS
$9.56B
| $2.5M | ﹤0.01% |
34,000
-9,400
| -22% | -$666K |
|
2745
Hilltop Holdings
HTH
$2.24B
| $2.5M | ﹤0.01% |
100,249
+20,779
| +26% | +$507K |
|
2746
AZZ Inc
AZZ
$4.54B
| $2.5M | ﹤0.01% |
54,372
+12,021
| +28% | +$491K |
|
2747
PUT
Encompass Health
EHC
$12.4B
| $2.49M | ﹤0.01% |
45,252
+44,498
| +5,902% | +$2.41M |
|
|
NVO
2748
PUT
Novo Nordisk
NVO
$209B
| $2.49M | ﹤0.01% |
86,000
+38,000
| +79% | +$1.05M |
|
2749
ProPetro Holding
PUMP
$1.35B
| $2.48M | ﹤0.01% |
220,566
+102,965
| +88% | +$920K |
|
2750
PUT
Delek US
DK
$3.58B
| $2.48M | ﹤0.01% |
73,900
| – | – |
|
Similar funds
Barclays's Q4 2019 Portfolio in Review
As of Q4 2019, Barclays held 7,254 positions worth $180B, up 13% from $160B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Barclays deployed $6.1B of net new capital in Q4 2019, opening 260 new positions and adding to 3,541 existing holdings. Its largest new stake was Pacer iPath Gold ETNs: 1,000,000 shares worth $25.3M.
By sector, the portfolio is most concentrated in Technology at 8.9% of assets, up from 7.7% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Invesco QQQ Trust, an estimated $605M trimmed.
- Barclays's largest Q4 2019 buy was Pacer iPath Gold ETNs: 1,000,000 shares worth $25.3M.
- Barclays added most to Apple in Q4 2019, an estimated $572M increase.
- Barclays's biggest Q4 2019 reduction was Invesco QQQ Trust, cutting an estimated $605M.
- Barclays fully exited Celgene Corp in Q4 2019, selling an estimated $411M.
- Barclays's ten largest holdings make up 26% of its $180B portfolio in Q4 2019.
- Barclays opened 260 new positions and closed 700 in Q4 2019.
- Barclays's portfolio value rose 13% quarter-over-quarter to $180B.
Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.